With Vera Elson
In a 9–2 en banc decision, a majority of the U.S. Court of Appeals for the Federal Circuit reaffirmed that the U.S. Patent Laws (35 U.S.C. § 112, ¶1) impose a written description requirement separate and apart from the enablement requirement. Ariad Pharmaceuticals, Inc. v. Ely Lilly & Co.